



CS/NSE&BSE/AFR/2020-21  
June 5, 2020

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. June 5, 2020, has taken on record and approved the Audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and for the year ended 31st March, 2020 and approved the following matters.

**1. Re-appointment**

We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at its meeting held today (June 05, 2020) has approved the re-appointment of Ms. Sudharani Jasti (DIN: 00277998) as Whole-time Director of the Company for a term of 3 years commencing from November 01, 2019 and subject to the approval of the members at the ensuing Annual General Meeting of the Company.

Pursuant to Regulation 30(2) read with Para-A of Part-A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we give below the information as prescribed for the re-appointment of Whole-time director.

|    |  |   |
|----|--|---|
| a) | reason for change                          | Re-appointment                                  |
| b) | date of appointment & term of appointment; | June 05, 2020<br>3 years from November 01, 2019 |

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

|    |   |  |
|----|---|--|
| c) | Brief profile of Whole-time Director          | Smt. Sudharani Jasti is a Graduate in Science from Andhra University; she returned from USA to India in 1988-89 and promoted this company in 1989. Smt. Sudharani Jasti had been on the Board since inception of the Company and successfully managing the company as Whole-time Director providing the right direction and leadership in all governance matters. Smt. Sudharani Jasti is the Co-founder and director on the Board since inception of the company. |
| d) | Disclosure of relationships between directors | Shri Venkateswarlu Jasti is spouse of Smt. Sudharani Jasti. Except this relationship, both the Directors are not related to any other Directors on the Board of the Company.   |

## 2. AGM Date

We are working on the date of 31<sup>st</sup> AGM for the financial year 2019-20 which will be intimated in due course.

3. Approved the enhancement of investment limits in WOS in USA Suven Neurosciences, Inc. from USD 50 Million upto USD 75 Million to undertake clinical developments on the various molecules in the pipeline.

Further, we are enclosing herewith the following documents:

- a) Audited Standalone and Consolidated Financial Results under Ind AS for the quarter and for the financial year ended 31st March, 2020
- b) Auditor's Reports of the Statutory Auditors on the Financial Results
- c) A copy of the Press Release of our company
- d) Declaration in respect of Audit Reports with unmodified opinion and
- e) Disclosure of details of Key Managerial Personnel ("KMP") for determining materiality under Regulation 30(5) of SEBI (LODR) Regulations, 2015

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 13:45 P.M.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**



**Shrenik Soni**  
Company Secretary  
Encl: as above

## Suven Life Sciences Limited



## SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, 6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

### STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2020.

Rs. In Lakhs

| PART - I |   | STANDALONE            |                  |                   |                    |                  |
|----------|---|-----------------------|------------------|-------------------|--------------------|------------------|
| Sl. No.  | PARTICULARS   | For the Quarter Ended |                  |                   | For the year ended |                  |
|          |   | 31/03/2020            | 31/12/2019       | 31/03/2019        | 31/03/2020         | 31/03/2019       |
|          |   | Ref note No.8         | un-Audited       | Ref note No.8     | Audited            | Audited          |
|          |   | (1)                   | (2)              | (3)               | (4)                | (5)              |
| 1        | <b>Income</b>   |                       |                  |                   |                    |                  |
|          | Revenue from operations   | 866.00                | 277.26           | 237.99            | 1,441.47           | 28,566.97        |
|          | Other Income  | 299.71                | 585.53           | 579.03            | 1,403.63           | 2,724.50         |
|          | <b>Total income</b>   | <b>1,165.71</b>       | <b>862.79</b>    | <b>817.02</b>     | <b>2,845.10</b>    | <b>31,291.47</b> |
| 2        | <b>Expenses</b>   |                       |                  |                   |                    |                  |
|          | a) Cost of materials consumed   | -                     | -                | -                 | -                  | 7,961.69         |
|          | b) Changes in inventories of finished goods, work-in-progress and stock-in-trade  | -                     | -                | -                 | -                  | (929.28)         |
|          | c) Employee benefits expense  | 348.16                | 242.29           | 211.45            | 1,459.51           | 3,384.64         |
|          | d) Finance costs  | 23.21                 | 9.81             | 29.07             | 54.03              | 190.26           |
|          | e) Depreciation and amortisation expense  | 105.24                | 85.50            | 80.18             | 416.87             | 1,078.97         |
|          | f) Manufacturing Expenses   | -                     | -                | -                 | -                  | 4,825.55         |
|          | g) R & D Expenses   | 576.33                | 638.55           | 1,481.15          | 2,594.44           | 5,936.86         |
|          | h) Other Expenses   | 149.25                | 332.57           | 360.10            | 913.86             | 2,517.40         |
|          | <b>Total expenses</b>   | <b>1,202.19</b>       | <b>1,308.72</b>  | <b>2,161.95</b>   | <b>5,438.71</b>    | <b>24,966.09</b> |
| 3        | <b>Profit before exceptional items &amp; Tax (1-2)</b>                            | <b>(36.48)</b>        | <b>(445.93)</b>  | <b>(1,344.93)</b> | <b>(2,593.61)</b>  | <b>6,325.38</b>  |
| 4        | Exceptional Items   | -                     | -                | -                 | -                  | -                |
| 5        | <b>Profit before Tax (3-4)</b>  | <b>(36.48)</b>        | <b>(445.93)</b>  | <b>(1,344.93)</b> | <b>(2,593.61)</b>  | <b>6,325.38</b>  |
| 6        | <b>Tax Expenses</b>   |                       |                  |                   |                    |                  |
|          | a) Current tax  | 197.18                | -                | (298.50)          | 197.18             | 1,298.62         |
|          | b) Deferred tax   | 22.69                 | 4.22             | (108.68)          | (1,415.47)         | 1,107.39         |
| 7        | <b>Net Profit/ (Loss) for the period/year(5-6)</b>                                | <b>(256.35)</b>       | <b>(450.15)</b>  | <b>(937.75)</b>   | <b>(1,375.32)</b>  | <b>3,919.37</b>  |
| 8        | <b>Other Comprehensive Income</b>   |                       |                  |                   |                    |                  |
| 8.a      | (i) Items that will not be reclassified to profit or loss                         | (28.88)               | (14.41)          | 10.59             | (45.41)            | (21.16)          |
|          | (ii) Income tax relating to items that will not be reclassified to profit or loss | 10.09                 | 5.04             | (3.70)            | 15.87              | 7.39             |
| 8.b      | (i) Items that will be reclassified to profit or loss                             | -                     | -                | -                 | -                  | -                |
|          | (ii) Income tax relating to items that will be reclassified to profit or loss     | -                     | -                | -                 | -                  | -                |
|          | <b>Total other Comprehensive Income</b>   | <b>(18.79)</b>        | <b>(9.37)</b>    | <b>6.89</b>       | <b>(29.54)</b>     | <b>(13.77)</b>   |
| 9        | <b>Total Comprehensive Income for the period (7+8)</b>                            | <b>(275.14)</b>       | <b>(459.52)</b>  | <b>(930.86)</b>   | <b>(1,404.86)</b>  | <b>3,905.60</b>  |
| 10       | <b>Paid-up equity share capital</b>   | <b>1,272.82</b>       | <b>1,272.82</b>  | <b>1,272.82</b>   | <b>1,272.82</b>    | <b>1,272.82</b>  |
|          | Face Value of the Share   | Re.1.00               | Re.1.00          | Re.1.00           | Re.1.00            | Re.1.00          |
| 11       | <b>Other Equity</b>   |                       |                  |                   | <b>37,494.53</b>   | <b>38,899.39</b> |
| 12       | <b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>                      |                       |                  |                   |                    |                  |
|          | a) Basic  | (0.20)                | (0.35)           | (0.74)            | (1.08)             | 3.08             |
|          | b) Diluted  | (0.20)                | (0.35)           | (0.74)            | (1.08)             | 3.08             |
|          |   | (not annualised)      | (not annualised) | (not annualised)  |                    |                  |



| PART - I |   | CONSOLIDATED          |                     |                     |                     |                     |
|----------|---|-----------------------|---------------------|---------------------|---------------------|---------------------|
|          |   | For the Quarter Ended |                     |                     | For the year ended  |                     |
| Sl. No.  | PARTICULARS   | 31/03/2020            | 31/12/2019          | 31/03/2019          | 31/03/2020          | 31/03/2019          |
|          |   | Ref note No.8         | un-Audited          | Ref note No.8       | Audited             | Audited             |
|          |   | (1)                   | (2)                 | (3)                 | (4)                 | (5)                 |
| 1        | Income  |                       |                     |                     |                     |                     |
|          | Revenue from operations   | 866.00                | 277.26              | 237.99              | 1,441.47            | 28,566.97           |
|          | Other Income  | 299.71                | 585.53              | 579.03              | 1,403.63            | 2,724.50            |
|          | Total income  | 1,165.71              | 862.79              | 817.02              | 2,845.10            | 31,291.47           |
| 2        | Expenses  |                       |                     |                     |                     |                     |
|          | a) Cost of materials consumed   | -                     | -                   | -                   | -                   | 7,961.69            |
|          | b) Changes in inventories of finished goods, work-in-progress                     | -                     | -                   | -                   | -                   | (929.28)            |
|          | c) Employee benefits expense  | 433.21                | 332.26              | 282.14              | 1,740.91            | 3,649.29            |
|          | d) Finance costs  | 23.23                 | 10.21               | 29.40               | 55.14               | 191.33              |
|          | e) Depreciation and amortisation  | 105.24                | 85.50               | 80.18               | 416.87              | 1,078.97            |
|          | f) Manufacturing Expenses   | -                     | -                   | -                   | -                   | 4,870.09            |
|          | g) R & D Expenses   | 2,783.77              | 2,370.78            | 4,397.26            | 10,322.64           | 11,894.33           |
|          | h) Other Expenses   | 156.21                | 341.18              | 378.36              | 949.62              | 2,559.44            |
|          | Total expenses  | 3,501.66              | 3,139.93            | 5,167.34            | 13,485.18           | 31,275.86           |
| 3        | Profit before exceptional items, Tax (1-2)  | (2,335.95)            | (2,277.14)          | (4,350.32)          | (10,640.08)         | 15.60               |
| 4        | Exceptional Items   | -                     | -                   | -                   | -                   | -                   |
| 5        | Profit before Tax (3-4)   | (2,335.95)            | (2,277.14)          | (4,350.32)          | (10,640.08)         | 15.60               |
| 6        | Tax Expenses  |                       |                     |                     |                     |                     |
|          | a) Current tax  | 197.18                | -                   | (298.50)            | 197.18              | 1,298.62            |
|          | b) Deferred tax   | 22.69                 | 4.22                | (108.68)            | (1,415.47)          | 1,107.39            |
| 7        | Net Profit/ (Loss) for the period/year (5-6)                                      | (2,555.82)            | (2,281.36)          | (3,943.14)          | (9,421.79)          | (2,390.41)          |
| 8        | Other Comprehensive Income  |                       |                     |                     |                     |                     |
| 8.a      | (i) Items that will not be reclassified to profit or loss                         | (28.89)               | (14.41)             | 10.59               | (45.41)             | (21.16)             |
|          | (ii) Income tax relating to items that will not be reclassified to profit or loss | 10.10                 | 5.03                | (3.71)              | 15.87               | 7.39                |
| 8.b      | (i) Items that will be reclassified to profit or loss                             | -                     | -                   | -                   | -                   | -                   |
|          | (ii) Income tax relating to items that will be reclassified to profit or loss     | -                     | -                   | -                   | -                   | -                   |
|          | Total other Comprehensive Income  | (18.79)               | (9.38)              | 6.88                | (29.54)             | (13.77)             |
| 9        | Total Comprehensive Income for the period (7+ 8)                                  | (2,574.61)            | (2,290.74)          | (3,936.26)          | (9,451.33)          | (2,404.18)          |
| 10       | Paid-up equity share capital<br>Face Value of the Share                           | 1,272.82<br>Re.1.00   | 1,272.82<br>Re.1.00 | 1,272.82<br>Re.1.00 | 1,272.82<br>Re.1.00 | 1,272.82<br>Re.1.00 |
| 11       | Other Equity  | -                     | -                   | -                   | 13,062.02           | 22,640.16           |
| 12       | Earning Per Share (EPS) (Face value of Rs.1/- each) :                             |                       |                     |                     |                     |                     |
|          | a) Basic  | (2.01)                | (1.79)              | (3.10)              | (7.40)              | (1.88)              |
|          | b) Diluted  | (2.01)                | (1.79)              | (3.10)              | (7.40)              | (1.88)              |
|          |   | (not annualised)      | (not annualised)    | (not annualised)    |                     |                     |



**NOTES:-**

1.The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on June 05, 2020.

2.The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

Consequently, the figures in Column (5) represent Demerged Undertaking & Research and development Business for the period 01-04-2018 to 30-09-2018 (i.e. PRE DEMERGER) and figures for the subsequent period 01-10-2018 to 31-03-2019 (POST DEMERGER) in Column (5) are of Research and development Business as a result of demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018. To that extent current quarter and year numbers are not comparable with previous periods presented.

3.The Company (SLSL) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable SPL to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the Company is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.

4. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5. The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance , 2019.

6.The COVID-19 impact on the business and going concern assumption of SLSL and its subsidiary: COVID-19 had not impacted the company's research operations, which includes our subsidiary, Suven Neurosciences, Inc. However, we are foreseeing certain delays in enrollment of ongoing phase 2 clinical studies conducted in the USA.

7. Impact of Fire accident that occurred subsequent to the Balance Sheet date:


On April 26, 2020 fire incident occurred in one of the buildings in our research facilities located at Jeedimetla, Hyderabad. This incident has no major impact on our regular operations, however early stage drug discovery is impacted. The company's properties are fully covered through insurance policies. The replacement cost of damaged equipment is being assessed by the surveyors.

8.The figures for the quarters ended March 31, 2020 and March 31, 2019 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto third quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.

9. The corresponding previous period figures have been regrouped / reclassified where ever necessary.

10.The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com

Place : Hyderabad  
Date : June 05, 2020



For SUVEN LIFE SCIENCES LTD

*Venkata Jasti*

**VENKAT JASTI**  
Chairman & CEO  
DIN: 00278028



# SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034


## Statement of Assets & Liabilities

Rs.in Lakhs

| Particulars                              | Standalone as at |                  | Consolidated as at |                  |
|--|------------------|------------------|--------------------|------------------|
|  | 31/03/2020       | 31/03/2019       | 31/03/2020         | 31/03/2019       |
| <b>A ASSETS</b>                          |                  |                  |                    |                  |
| <b>1 Non-current assets</b>              |                  |                  |                    |                  |
| (a) Property, Plant and Equipment        | 2,063.88         | 2,235.02         | 2,063.88           | 2,235.02         |
| (b) Capital Work-in-Progress             | -                | 1.81             | -                  | 1.81             |
| (c) Other Intangible Assets              | 15.13            | -                | 15.13              | -                |
| (d) Right of use Assets                  | 390.36           | -                | 390.36             | -                |
| (e) Financial Assets                     |                  |                  |                    |                  |
| I. Investments                           | 24,181.31        | 13,636.33        | -                  | -                |
| II. Loans                                | 9,125.25         | -                | 9,125.25           | -                |
| <b>Total Non-Current assets</b>          | <b>35,775.93</b> | <b>15,873.16</b> | <b>11,594.62</b>   | <b>2,236.83</b>  |
| <b>2 Current assets</b>                  |                  |                  |                    |                  |
| (a) Financial Assets                     |                  |                  |                    |                  |
| I. Investments                           | 4.94             | 22,292.82        | 4.94               | 22,292.82        |
| II. Trade Receivables                    | 227.05           | 264.43           | 227.05             | 264.43           |
| III. Cash and Cash equivalents           | 70.76            | 1.27             | 1,467.57           | 22.75            |
| IV. Bank balances other than (III) above | 41.65            | 45.79            | 41.65              | 45.79            |
| V. Loans                                 | 4,200.70         | 4,749.82         | 4,200.70           | 4,749.82         |
| VI. Other Financial assets               | -                | -                | 2.05               | 1.89             |
| (b) Current Tax asset (net)              | 458.10           | 408.03           | 458.10             | 408.02           |
| (c) Other current assets                 | 196.56           | 313.39           | 196.56             | 313.39           |
| <b>Total Current assets</b>              | <b>5,199.76</b>  | <b>28,075.55</b> | <b>6,598.62</b>    | <b>28,098.91</b> |
| <b>TOTAL - ASSETS</b>                    | <b>40,975.69</b> | <b>43,948.71</b> | <b>18,193.24</b>   | <b>30,335.74</b> |
| <b>B EQUITY AND LIABILITIES</b>          |                  |                  |                    |                  |
| <b>1 EQUITY</b>                          |                  |                  |                    |                  |
| (a) Equity Share Capital                 | 1,272.82         | 1,272.82         | 1,272.82           | 1,272.82         |
| (b) Other Equity                         | 37,494.53        | 38,899.39        | 13,062.02          | 22,640.16        |
| <b>Total Equity</b>                      | <b>38,767.35</b> | <b>40,172.21</b> | <b>14,334.84</b>   | <b>23,912.98</b> |
| <b>2 LIABILITIES</b>                     |                  |                  |                    |                  |
| (a) Financial Liabilities                |                  |                  |                    |                  |
| I. Lease Liabilities                     | 293.50           | -                | 293.50             | -                |
| II. Borrowings                           | 108.49           | 177.54           | 108.49             | 177.54           |
| (b) Provisions                           | 172.07           | 148.62           | 172.07             | 148.62           |
| (c) Other non current liabilities        | 46.63            | 75.70            | 46.63              | 75.70            |
| (d) Deferred tax Liabilities (net)       | 586.60           | 2,048.81         | 586.60             | 2,048.81         |
| <b>Total non-current liabilities</b>     | <b>1,207.29</b>  | <b>2,450.67</b>  | <b>1,207.29</b>    | <b>2,450.67</b>  |
| <b>Current liabilities</b>               |                  |                  |                    |                  |
| (a) Financial Liabilities                |                  |                  |                    |                  |
| I. Lease Liabilities                     | 104.87           | -                | 104.87             | -                |
| II. Trade payables                       |                  |                  |                    |                  |
| a) To Micro & Small Enterprises          | 28.42            | -                | 28.42              | -                |
| b) Other than Micro & Small Enterprises  | 549.78           | 708.59           | 549.78             | 708.59           |
| III. Other Financial Liabilities         | 180.12           | 489.98           | 1,830.18           | 3,136.24         |
| (b) Other Current liabilities            | 64.57            | 64.07            | 64.57              | 64.07            |
| (c) Provision Employee benefits          | 73.30            | 63.19            | 73.30              | 63.19            |
| <b>Total - Current liabilities</b>       | <b>1,001.06</b>  | <b>1,325.83</b>  | <b>2,651.12</b>    | <b>3,972.09</b>  |
| <b>Total Liabilities</b>                 | <b>2,208.34</b>  | <b>3,776.50</b>  | <b>3,858.40</b>    | <b>6,422.76</b>  |
| <b>TOTAL - EQUITY AND LIABILITIES</b>    | <b>40,975.69</b> | <b>43,948.71</b> | <b>18,193.24</b>   | <b>30,335.74</b> |

For Suvén Life Sciences Ltd

Place : Hyderabad  
Date: June 05, 2020

  
Venkat Jasti  
Chairman & CEO




**SUVEN LIFE SCIENCES LIMITED**
**Standalone Statement of Cash flows for the period ended 31st March, 2020**

Rs.in Lakhs

| Particulars  | For the year ended<br>March 31, 2020 | For the year ended<br>March 31, 2019 |
|--|--------------------------------------|--------------------------------------|
| <b>A. Cash flow from operating activities</b>                          |                                      |                                      |
| Profit/(Loss) before tax   | (2,593.61)                           | 6,325.38                             |
| <b>Adjustments :</b>   |                                      |                                      |
| Depreciation and amortisation expense                                  | 396.33                               | 1,419.74                             |
| Interest Income  | 1,321.31                             | (18.62)                              |
| Finance Cost   | 54.03                                | 190.26                               |
| Gain on sale of Current Investment                                     | 50.22                                | (2,079.76)                           |
| <b>Operating profit before working capital changes</b>                 | <b>(771.72)</b>                      | <b>5,836.99</b>                      |
| <b>Adjustments for (Increase)/decrease in operating assets</b>         |                                      |                                      |
| Trade Receivables  | 37.38                                | (371.67)                             |
| Inventories  | -                                    | (54.29)                              |
| Other non current financial assets                                     | (9,125.25)                           | (1.03)                               |
| Other non current assets   | (390.36)                             | (2,124.60)                           |
| Other current financial assets   | 549.12                               | (4,754.39)                           |
| Other current assets   | 116.83                               | 278.98                               |
| <b>Adjustments for Increase/(decrease) in operating liabilities</b>    |                                      |                                      |
| Trade Payables   | (130.39)                             | (600.86)                             |
| Long term provisions   | 23.43                                | 85.89                                |
| Other non-current liabilities  | (29.06)                              | (29.06)                              |
| Short term provision   | (35.29)                              | 7.01                                 |
| Other financial liabilities  | (309.86)                             | 2,075.39                             |
| Other current liabilities  | 0.50                                 | (57.72)                              |
| <b>Cash generated from operating activities</b>                        | <b>(10,064.68)</b>                   | <b>290.65</b>                        |
| Income taxes paid (net of refunds)                                     | 278.12                               | 1,491.86                             |
| <b>Net Cash flows from operating activities</b>                        | <b>(10,342.80)</b>                   | <b>(1,201.21)</b>                    |
| <b>B. Cash flow from Investing activities</b>                          |                                      |                                      |
| Payments for Purchase of property, plant and equipment                 | (238.51)                             | (3,949.89)                           |
| Proceeds from sale of Property, plant & equipment                      | -                                    | -                                    |
| Changes in Investments   | (10,544.97)                          | (3,413.74)                           |
| Sale/(purchase) of mutual funds  | 22,237.66                            | 7,659.50                             |
| Bank balances not considered as cash and cash equivalents              | 4.13                                 | 5.35                                 |
| Interest received  | (1,321.31)                           | 18.62                                |
| <b>Net cash flow from /( used in) investing activities</b>             | <b>10,137.00</b>                     | <b>319.83</b>                        |
| <b>C. Cash flows from financing activities</b>                         |                                      |                                      |
| (Repayment)/Proceeds from long term borrowings                         | (69.04)                              | 63.66                                |
| (Repayment)/Proceeds from short term borrowings                        | -                                    | 581.15                               |
| Changes In Lease Liability   | 398.36                               | -                                    |
| Finance Cost   | (54.03)                              | (190.26)                             |
| Dividends paid to equity holders (including dividend distribution tax) | -                                    | -                                    |
| <b>Net cash flow from /(used In) financing activities</b>              | <b>275.29</b>                        | <b>454.54</b>                        |
| Net increase/(decrease) in cash and cash equivalents                   | 69.49                                | (426.84)                             |
| Cash and cash equivalents as at the beginning of the year              | 1.27                                 | 1,099.70                             |
| Add: adjustment due to Demerger  |                                      | (671.58)                             |
| <b>Cash and cash equivalents at the end of the year</b>                | <b>70.76</b>                         | <b>1.27</b>                          |
| Cash and cash equivalents  | 70.76                                | 1.27                                 |
| Balances per statement of cash flows                                   | 70.76                                | 1.27                                 |


For Suven Life Sciences Ltd



 Venkat Jasti  
 Chairman & CEO

Place : Hyderabad

Date: June 05, 2020




**SUVEN LIFE SCIENCES LIMITED****Consolidated Statement of Cash flows for the period ended 31st March, 2020**

Rs.in Lakhs

| Particulars  | For the year ended<br>March 31, 2020 | For the year ended<br>March 31, 2019 |
|--|--------------------------------------|--------------------------------------|
| <b>A. Cash flow from operating activities</b>                          |                                      |                                      |
| Profit/(Loss) before tax   | (10,640.08)                          | 15.60                                |
| <b>Adjustments :</b>   |                                      |                                      |
| Depreciation and amortisation expense                                  | 396.33                               | 1,419.74                             |
| Interest Income  | 1,321.31                             | (18.62)                              |
| Finance Cost   | 55.14                                | 191.33                               |
| Gain on sale of Current Investment                                     | 50.22                                | (2,079.76)                           |
| <b>Operating profit before working capital changes</b>                 | <b>(8,817.08)</b>                    | <b>(471.72)</b>                      |
| <b>Adjustments for (Increase)/decrease in operating assets</b>         |                                      |                                      |
| Trade Receivables  | 37.38                                | (371.67)                             |
| Inventories  | -                                    | (54.29)                              |
| Other non current financial assets                                     | (9,125.25)                           | (1.03)                               |
| Other non current assets   | (390.36)                             | (2,124.60)                           |
| Other current financial assets   | 548.96                               | (4,754.49)                           |
| Other current assets   | 116.83                               | 278.98                               |
| <b>Adjustments for Increase/(decrease) in operating liabilities</b>    |                                      |                                      |
| Trade Payables   | (130.39)                             | (600.86)                             |
| Long term provisions   | 23.43                                | 85.89                                |
| Other non-current liabilities  | (29.06)                              | (29.06)                              |
| Short term provision   | (35.29)                              | 7.01                                 |
| Other financial liabilities  | (1,306.06)                           | 4,324.02                             |
| Other current liabilities  | 0.50                                 | (57.72)                              |
| <b>Cash generated from operating activities</b>                        | <b>(19,106.40)</b>                   | <b>(3,769.52)</b>                    |
| Income taxes paid (net of refunds)                                     | 278.12                               | 1,491.86                             |
| <b>Net Cash flows from operating activities</b>                        | <b>(19,384.52)</b>                   | <b>(5,261.38)</b>                    |
| <b>B. Cash flow from Investing activities</b>                          |                                      |                                      |
| Payments for Purchase of property, plant and equipment                 | (238.51)                             | (3,949.89)                           |
| Sale/(purchase) of mutual funds  | 22,237.66                            | 7,659.50                             |
| Foreign currency translation reserve                                   | (126.81)                             | (20.12)                              |
| Bank balances not considered as cash and cash equivalents              | 4.13                                 | 5.35                                 |
| Interest received  | (1,321.31)                           | 18.62                                |
| <b>Net cash flow from /(used in) investing activities</b>              | <b>20,555.17</b>                     | <b>3,713.46</b>                      |
| <b>C. Cash flows from financing activities</b>                         |                                      |                                      |
| (Repayment)/Proceeds from long term borrowings                         | (69.04)                              | 63.66                                |
| (Repayment)/Proceeds from short term borrowings                        | -                                    | 581.15                               |
| Changes In Lease Liability   | 398.36                               | -                                    |
| Finance Cost   | (55.14)                              | (191.33)                             |
| Dividends paid to equity holders (including dividend distribution tax) | -                                    | -                                    |
| <b>Net cash flow from /(used in) financing activities</b>              | <b>274.18</b>                        | <b>453.47</b>                        |
| Net increase/(decrease) in cash and cash equivalents                   | 1,444.83                             | (1,094.45)                           |
| Cash and cash equivalents as at the beginning of the year              | 22.75                                | 1,788.79                             |
| Add: adjustment due to Demerger  |                                      | (671.58)                             |
| <b>Cash and cash equivalents at the end of the year</b>                | <b>1,467.58</b>                      | <b>22.76</b>                         |
| Cash and cash equivalents  | 1,467.57                             | 22.75                                |
| Balances per statement of cash flows                                   | 1,467.57                             | 22.75                                |

For Suven Life Sciences Ltd



Venkat Jasti  
Chairman & CEO

Place : Hyderabad

Date: June 05, 2020





**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF SUVEN LIFE SCIENCES LIMITED**

**Opinion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2020 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2020 ("the Statement") of SUVEN LIFE SCIENCES LIMITED ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2020:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2020**

With respect to the Standalone Financial Results for the quarter ended March 31, 2020, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



## **Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2020**


We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“the ICAI”) together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management’s Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company’s Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2020 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and Fairview and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company’s ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company. Auditor’s Responsibilities



05/06/2020

**(a) Audit of the Standalone Financial Results for the year ended March 31,2020**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2020 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results
- Represent the underlying transactions and events in a manner that achieves fair



05/06/2020

presentation.

- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Standalone Financial Results for the quarter ended March 31, 2020**

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements (“SRE”) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Other Matters**

- Attention is drawn to Note 8 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the current financial year after giving effect of the Scheme as referred in the Note 2 of the financial results which were subject to limited review by us. Our report is not modified in respect of this matter.
- Attention is drawn to Note 8 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for




05/06/2020

the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report is not modified in respect of this matter.

For **TUKARAM & CO LLP**,  
Chartered Accountants  
(Firm Registration No.004436S)



**RAJENDER REDDY K**  
Partner  
Membership No.231834  
UDIN: 20231834AAAABH4075



Place: Hyderabad  
Date: June 05, 2020.



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF SUVEN LIFE SCIENCES LIMITED**

**Opinion and Conclusion**

We have(a) audited the Consolidated Financial Results for the year ended March31,2020 and (b)reviewed the Consolidated Financial Results for the quarter ended March31,2020 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Consolidated Financial Results for the quarter and year ended March 31, 2020" of **SUVEN LIFE SCIENCES LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") for the quarter and year ended March 31, 2020, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

**(a) Opinion on Annual Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2020:

- (i) includes the results of the following entities:

| Name of the Company     | Country | Relationship            |
|-------------------------|---------|-------------------------|
| SUVEN NUEROSCIENCES INC | USA     | Wholly Owned Subsidiary |

- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31,2020.

**(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2020**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2020, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2020 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2020, prepared in accordance with the



05/06/2020

recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

### **Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2020**


We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (the “Act”). Our responsibilities under those Standards are further described in paragraph(a) of Auditor’s Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

### **Management’s Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent’s Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2020, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the consolidated net profit/loss and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of



05/06/2020

Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group

### **Auditor's Responsibilities for**

#### **(a) Audit of the Consolidated Financial Results for the year ended March 31, 2020**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2020 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.



05/06/2020

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors .For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.


Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Consolidated Financial Results for the quarter ended March 31,2020**

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



05/06/2020

The Statement includes the results of the entities as listed under paragraph(a)(i) of Opinion and Conclusion section above.

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

### Other Matters


- Attention is drawn to Note 8 to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year after giving effect of the Scheme as referred in the Note 2 of the financial results which were subject to limited review by us. Our report is not modified in respect of this matter.
- Attention is drawn to Note 8 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report is not modified in respect of this matter.
- We did not audit financial information of One subsidiary included in the consolidated financial results, whose financial information reflect total assets of Rs.1,398.86 lakhs as at March 31,2020 and total revenues of Rs. -NIL- for the year ended March 31, 2020, total net loss of Rs.(8,046.47) lakhs for year ended March 31, 2020 and total comprehensive income of Rs.(8,046.47) lakhs for the year ended March 31, 2020 and net cash inflows of Rs.(1.11) lakhs for the year ended March 31, 2020, as considered in the Statement. These financial information have been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **TUKARAM & CO LLP**,  
Chartered Accountants  
(Firm Registration No.004436S)



**RAJENDER REDDY K**  
Partner  
Membership No.231834  
UDIN: 20231834AAAABI5052



Place: Hyderabad  
Date: June 05, 2020.

05/06/2020

## News Release

**HYDERABAD, INDIA (5 June' 2020)** -- SUVEN Life Sciences Limited ("Suven", "Company") today announced audited financial results for the quarter and year ended 31 Mar 2020. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5 June' 2020 at Hyderabad.

### CONDENCED STATEMENT OF OPERATIONS

All figures in INR Lakhs, except EPS

|  | Stand Alone - 3 Months ended |                 |                 | FY-Stand Alone <sup>(b)</sup> |                  | FY-Consolidated <sup>(b)(d)</sup> |                   |
|--|------------------------------|-----------------|-----------------|-------------------------------|------------------|-----------------------------------|-------------------|
|  | Mar-20                       | Dec-19          | Mar-19          | Mar-20                        | Mar-19           | Mar-20                            | Mar-19            |
| Revenue  | 1,165.71                     | 862.79          | 817.02          | 2,845.10                      | 31,291.47        | 2,845.10                          | 31,291.47         |
| R&D and Operational expenses                       | 1,073.74                     | 1,213.41        | 2,052.70        | 4,967.81                      | 23,696.86        | 13,013.17                         | 30,005.56         |
| Depreciation and Amortization                      | 105.24                       | 85.50           | 80.18           | 416.87                        | 1,078.97         | 416.87                            | 1,078.97          |
| Finance cost                                       | 23.21                        | 9.81            | 29.07           | 54.03                         | 190.26           | 55.14                             | 191.33            |
| <b>Total expenses</b>                              | <b>1,202.19</b>              | <b>1,308.72</b> | <b>2,161.95</b> | <b>5,438.71</b>               | <b>24,966.09</b> | <b>13,485.18</b>                  | <b>31,275.86</b>  |
| Tax  | 219.87                       | 4.22            | (407.18)        | (1,218.29)                    | 2,406.01         | (1,218.29)                        | 2,406.01          |
| <b>Profit/(Loss) After Tax for the period/year</b> | <b>(256.35)</b>              | <b>(450.15)</b> | <b>(937.75)</b> | <b>(1,375.32)</b>             | <b>3,919.37</b>  | <b>(9,421.79)</b>                 | <b>(2,390.41)</b> |
| Other comprehensive income                         | (18.79)                      | (9.37)          | 6.89            | (29.54)                       | (13.77)          | (29.54)                           | (13.77)           |
| <b>Total comprehensive income</b>                  | <b>(275.14)</b>              | <b>(459.52)</b> | <b>(930.86)</b> | <b>(1,404.86)</b>             | <b>3,905.60</b>  | <b>(9,451.33)</b>                 | <b>(2,404.18)</b> |
| Paid up equity capital                             | 1,272.82                     | 1,272.82        | 1,272.82        | 1,272.82                      | 1,272.82         | 1,272.82                          | 1,272.82          |
| <b>Earnings per share of Rs.1 each (EPS)</b>       | <b>(0.20)</b>                | <b>(0.35)</b>   | <b>(0.74)</b>   | <b>(1.08)</b>                 | <b>3.08</b>      | <b>(7.40)</b>                     | <b>(1.88)</b>     |

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The Company has become Demerged entity effective 1 Oct 2018 and hence the annual figures of previous year are not comparable

(c) Post demerger, approved by Honorable National Company Law Tribunal (NCLT) on 6 Jan 2020, the CRAMS operations of the Company were demerged into Suven Pharmaceuticals Limited (the Resultant entity) and the Company continue to focus on NCE based Research and Development.

(d) Consolidated statement includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(e) Suven presented exploratory sub-group analyses data from completed Masupirdine (SUVN-502) Phase 2A proof of concept Study in Patients with Moderate Alzheimer's Disease (AD) at the **Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD™) focus meeting 2020** in April 2020. This meeting, originally scheduled to take place in Vienna, Austria, was converted to a virtual meeting due to the COVID-19 pandemic.

(f) Based on the encouraging results in sub-group analysis of SUVN-502 for some of the secondary endpoints, Suven is in consultation with KOL to finalize the indication for Phase 2 POC study. The same will be initiated before end of the year.

(g) Suven's ongoing phase 2 study in USA on SUVN-G3031, targeted against Narcolepsy (excessive day time sleep disorder), will be delayed by few months due to the impact of COVID-19 pandemic in USA.

(h) Since last reporting period, the Company has been granted 20 patents for its innovative drug discovery covering ARIPO, Brazil, Eurasia, Israel, Japan, Mexico, New Zealand, South Africa and South Korea.

Update on patents during this period can be viewed at: <http://suven.com/Patentupdates.aspx>

For more information on Suven please visit our Web site at <http://www.suven.com>

#### Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive;

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)



CS/NSE/BSE/2020-21  
June 05, 2020

To  
The General Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Declaration in respect of Audit Reports with unmodified opinion for the financial year ended 31st March 2020**

.....

We hereby declare that the Statutory Auditors of the Company, M/s. Tukaram & Co LLP Chartered Accountants have issued an Audit Reports with unmodified opinion on audited financial results (Standalone and Consolidated) for the quarter and year ended 31<sup>st</sup> March, 2020.

We request you to take this document on your record.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

**Venkateswarlu Jasti**  
Chairman & CEO

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)



CS/NSE/BSE/2020-21  
June 05, 2020

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Details of Key Managerial Personnel (“KMP”) for determining materiality under Regulation 30(5) of SEBI (Listing and Obligation Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30(5) of SEBI (Listing and Obligation Disclosure Requirements) Regulations, 2015, please find below the details of the Key Managerial Personnel who have been jointly severally authorized by the Board of Directors of the Company.

**To determine the materiality of an event or information under this regulation and also making disclosures to stock exchange(s):**

| <b>Name</b>              | <b>Designation</b>   | <b>E-mail ID</b>   |
|--------------------------|--|--------------------|
| Shri Venkateswarlu Jasti | Chairman & CEO   | jasti@suvenc.com   |
| Mr. M. Mohan Kumar       | Chief Financial Officer  | mohank@suvenc.com  |
| Mr. Shrenik Soni         | Company Secretary  | shrenik@suvenc.com |
| Contact Address:         | Suvenc Life Sciences Limited<br>SDE Serene Chambers, 6th Floor, Road No. 5,<br>Banjara Hills, Hyderabad – 500 034, Telangana |                    |
| Contact No.              | 040-2354 1142  |                    |

This is for your information and records.

Thanking you,  
Yours faithfully,  
For **Suvenc Life Sciences Limited**

**Shrenik Soni**  
Company Secretary

## Suvenc Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suvenc.com website: www.suvenc.com